Antibe Therapeutics (CVE:ATE, OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from Proactive Investors Vancouver to talk about a biotech company with a pipeline of drugs targeting pain and inflammation. Antibe's pipeline addresses significant unmet medical needs, especially concerning the safety and addictive properties of today's pain therapeutics. Legault also chatted with Proactive about a recently published paper in the British Journal of Pharmacology, providing extensive information about the successful Phase 2B safety trial for its lead drug.
Investor deep dive
Antibe Therapeutics is poised to disrupt the global pain management industry
Antibe Therapeutics is a potential game changer in pain management
Quick facts: Antibe Therapeutics
Market Cap: $113.49 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics named herein, including the promotion by the Company of Antibe Therapeutics in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE